close icon

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved.

However, the decline from the top at $77.12 a share in July, 2016, looked like a textbook Elliott Wave correction. Since the theory states that once a correction is over, the preceding trend resumes, we thought BMY was actually attractive below $50. Not to mention the fact that based on discounted future cash flows, the company was also undervalued.

In January, 2020, the price exceeded $68 a share. Then, the coronavirus crash gave investors another chance to join the bulls in the mid-$40s. Last week, Bristol Myers closed at $64.56, after reaching $67.13 on Tuesday. Can the rally continue this time around?

Bristol Myers stock looks bearish below $67

Fundamental valuation metrics suggest that even after a 45% surge, Bristol Myers is still undervalued. Management expects the company to average $15B a year in free cash flow going forward. Dividing its current market cap of $145B by $15B gives us a P/FCF lower than 10.

Approach Bristol Myers Stock With Caution Above $60

Unfortunately for the bulls, cheap stocks often get cheaper. The market is driven by emotions and cannot always be relied on to rationally value a business. The chart above, for instance, is giving us a good reason to be careful with Bristol-Myers near $65.

It shows the recovery from the March 2020 bottom at $45.76 to $67.13. It can easily be seen as a simple a-b-c zigzag, where wave ‘c’ is an ending diagonal. This is a corrective pattern, which means a notable bearish reversal can be expected. The next chart explains where does this structure fit into the bigger picture.

Bristol Myers can lose a third of its value

It turns out the decline from $77.12 in July, 2016, might still be in progress. For the past four years the stock price has been moving up and down in a narrowing range. “Triangle” is the first word that comes into mind when an Elliott Wave analyst sees something like that.

The weakness from $77.12 looks like an incomplete (W)-(X)-(Y) double zigzag, where wave (X) is a textbook triangle correction labeled A-B-C-D-E. If this count is correct, we can anticipate a ~40% plunge to sub-$40 a share in wave (Y). Once there, the post-2016 bear market should end and the risk/reward ratio would switch in favor of the bulls again.

Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!

Disclosure: The author plans to add to his long position in Bristol Myers stock if this analysis proves correct.



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

HZNP Stock Blows Past All Expectations. Now What?

We first covered Horizon Therapeutics, then Horizon Pharma, in September 2016. The stock was trading around $18 a share after a decline from the vicinity of $40. However, we didn’t think it was time to buy. The structure of the preceding rally ending in mid-2015 was impulsive and we thought the bears were not done…

Read More »

AZPN Stock Too Expensive for Its Own Good

Exceptional margins and returns on assets and equity make the surge in Aspen Technology shares easy to understand. AZPN stock exceeded $162 a share last week, up 122% from last year’s low at $73. On the other hand, the software company is expected to earn $5 a share in this fiscal year. This means the…

Read More »

Amerco Stock Carries Very High Risks Above $500

Amerco is a $10B moving and storage operations and insurance provider. The company is founded in 1945 and went public in the mid-1990s. The stock trades under the symbol UHAL and is currently hovering at all-time highs above $500 a share. The recovery from March 2020 was especially rewarding with Amerco stock rising 125% in…

Read More »

Anthem Stock Completes a Pattern it Started in 2001

With a market cap of $72B and 2020 sales of $122B, Anthem Inc. is one of the largest life, hospital and medical insurance providers in the U.S. The company went public in October 2001 and is one of not too many firms never to trade below its IPO price. Nearly twenty years ago, the stock…

Read More »

AJG Stock to Lose Half as Post-2009 Uptrend Ends

The pandemic disruptions hardly put a dent in Arthur J. Gallagher’s business. Despite slightly lower revenues, one of the largest insurance brokers in the world achieved its highest profit ever in 2020. As a result, AJG stock climbed to a new all-time high of $129 in December. Currently hovering around $116, the stock still looks…

Read More »

S&P Global Can Disappoint in Next Couple of Years

In July last year we wrote an Elliott Wave analysis highlighting the possibility of a notable 40%+ correction in Moody’s stock. Seven months later now, the share price is little changed and the negative outlook remains valid. Today, we are going to examine Moody’s major rival – S&P Global Inc. S&P Global is a ratings…

Read More »

SBAC Stock to Reach New High Before Bears Show Up

SBA Communications is a real estate investment trust, providing wireless communications infrastructure to companies like Verizon and AT&T. SBAC went public in mid-1999, only to participate in the final months of the dot-com bubble before it all came crashing down. The stock exceeded $57 a share in the summer of 2000. By late-2002, it could…

Read More »

More analyses